The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -22,227,852 |
| Stock-based compensation expense | 6,046,661 |
| Change in estimated fair value of warrant liability | 0 |
| Gain on settlement of warrant liability | 0 |
| Loss on issuance of related party convertible notes payable at fair value | 0 |
| Change in estimated fair value of related party convertible notes payable | 0 |
| Interest accrued on license payable | 20,250 |
| Prepaid assets and other current assets | -82,282 |
| Other assets | -110,548 |
| Accounts payable | -512,536 |
| Accrued compensation | -300,145 |
| Accrued interest | -70,957 |
| Other accrued expenses | -2,354,504 |
| Net cash used in operating activities | -19,206,253 |
| Proceeds from issuance of shares of common stock under underwritten public offering, net of underwriting discounts and offering costs | 15,573,966 |
| Proceeds from issuance of shares of common stock under june 2025 private placement, net | 4,592,462 |
| Proceeds from issuance of shares of common stock under the committed equity facility, net | 3,826,336 |
| Proceeds from the exercise of stock options | 34,115 |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 0 |
| Payment of offering costs related to initial public offering | 0 |
| Proceeds from issuance of related party short-term loan | 0 |
| Payment of related party short-term loan | 0 |
| Proceeds from issuances of related party convertible notes payable | 0 |
| Deferred offering costs | 302,825 |
| Net cash provided by financing activities | 23,724,054 |
| Net change in cash and cash equivalents | 4,517,801 |
| Cash and cash equivalents, beginning of period | 8,641,622 |
| Cash and cash equivalents, end of period | 13,159,423 |
ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC. (ACTU)